menu

New Insights into the Management of CKD in T2D: The Role of MRA Therapies

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

New Insights into the Management of CKD in T2D: The Role of MRA Therapies

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Achieving optimal outcomes in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remains a challenge, and treating physicians need to embrace multidisciplinary components when managing progression to CKD.

    In this discussion, Drs. Gerasimos Filippatos, Peter Rossing, and Matthew Weir review the unmet needs of patients with CKD and T2D. They also explore the role of mineralocorticoid receptor antagonists (MRAs) in the treatment spectrum and review recent findings from clinical trials. Tune in to ensure you’re doing all you can for each of your patients.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Peter Rossing, DMSc, MD
    Professor, Diabetic Angiopathy
    University of Copenhagen
    Copenhagen, Denmark 
    Peter Rossing has nothing to disclose

    Faculty:
    Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
    Professor of Cardiology, National and Kapodistrian University of Athens
    Chair, Department of Cardiology
    Athens University Hospital Attikon
    Chaidari, Greece 
    Consulting Fees: Boehringer Ingelheim, Servier
    Commercial Interest Speakers Bureau: Boehringer Ingelheim, Novartis
    Contracted Research: Amgen, Bayer, Vifor Pharma

    Matthew R. Weir, MD
    Division Head, Nephrology
    University of Maryland
    School of Medicine
    Baltimore, MD
    Consulting Fees: AstraZeneca, Boehringer-Ingelheim, Janssen, Merck, Relypsa, Vifor Pharma

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the role nonsteroidal MRAs play in optimizing cardiorenal outcomes in the management of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D)
    • Translate recent efficacy and safety data for MRAs into CKD treatment selection for patients with T2D
    • Individualize therapy selection based on the individual needs of patients with CKD and T2D

  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, endocrinologists, cardiologists, and primary care physicians.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Bayer AG.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Achieving optimal outcomes in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) remains a challenge, and treating physicians need to embrace multidisciplinary components when managing progression to CKD.

    In this discussion, Drs. Gerasimos Filippatos, Peter Rossing, and Matthew Weir review the unmet needs of patients with CKD and T2D. They also explore the role of mineralocorticoid receptor antagonists (MRAs) in the treatment spectrum and review recent findings from clinical trials. Tune in to ensure you’re doing all you can for each of your patients.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Peter Rossing, DMSc, MD
    Professor, Diabetic Angiopathy
    University of Copenhagen
    Copenhagen, Denmark 
    Peter Rossing has nothing to disclose

    Faculty:
    Gerasimos S. Filippatos, MD, FESC, FHFA, FHFSA(h)
    Professor of Cardiology, National and Kapodistrian University of Athens
    Chair, Department of Cardiology
    Athens University Hospital Attikon
    Chaidari, Greece 
    Consulting Fees: Boehringer Ingelheim, Servier
    Commercial Interest Speakers Bureau: Boehringer Ingelheim, Novartis
    Contracted Research: Amgen, Bayer, Vifor Pharma

    Matthew R. Weir, MD
    Division Head, Nephrology
    University of Maryland
    School of Medicine
    Baltimore, MD
    Consulting Fees: AstraZeneca, Boehringer-Ingelheim, Janssen, Merck, Relypsa, Vifor Pharma

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the role nonsteroidal MRAs play in optimizing cardiorenal outcomes in the management of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D)
    • Translate recent efficacy and safety data for MRAs into CKD treatment selection for patients with T2D
    • Individualize therapy selection based on the individual needs of patients with CKD and T2D

  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, endocrinologists, cardiologists, and primary care physicians.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Bayer AG.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule15 Aug 2022
Webpack App